CONFIDENTIAL
        TREATMENT REQUESTED: Certain portions of this document have been omitted
        pursuant to a request for confidential treatment and, where applicable, have
        been marked with an asterisk (“ [****] ”)
        to
        denote where omissions have been made. Note that four pages of this exhibit
        contain omitted material pursuant to this request. The confidential material
        has
        been filed separately with the Securities and Exchange
        Commission.


genzyme
                PHARMACEUTICALS
              GENZYME
                  CORPORATION
                CNE
                  KENDALL SQUARE
                CAMBRIDGE,
                  MA 02139-1562, USA
                617-252-7500
                FAX
                  617-252-7772
                www.genzyme.com




**AMENDED
        AND RESTATED SUPPLY AGREEMENT**
  THIS
        AMENDED AND RESTATED SUPPLY AGREEMENT (“ Agreement”)
        dated as of October
        8, 2003,
        is
        by and between Genzyme Corporation, with principal offices located at One
        Kendall Square, Cambridge, Massachusetts 02139 ("Vendor") and Photogen
        Technologies, Inc., through its IMCOR Pharmaceutical Division, a Nevada
        corporation with its principal offices located at 6175 Lusk Boulevard, San
        Diego, California 92121 ("IMCOR").
  WHEREAS,
        Vendor entered into a Supply Agreement with Alliance Pharmaceutical Corp.
        dated
        as of May 16, 2000 (the "Original Supply Agreement");
  WHEREAS,
        Photogen Technologies, Inc. has acquired the business of Alliance Pharmaceutical
        Corp. to which the Original Supply Agreement relates;
  WHEREAS,
        IMCOR and Vendor now desire to modify the terms of their relationship and
        amend
        and restate the Original Supply Agreement as provided herein;
  WHEREAS,
        Vendor has by virtue of its proprietary technologies and know-how developed
        and
        manufactures or by virtue of its distribution relationship with the manufacturer
        has adequate access to the material described on Exhibit "A" attached hereto
        (the "Material"); and
  WHEREAS, IMCOR
        desires to secure a long-term supply of commercial quantities  of
        the
        Material for its product described on Exhibit "A" (the "Product") if and
        when
        such Product is
        approved by the FDA and Vendor is willing to supply such quantities of its
        Material to IMCOR as IMCOR's exclusive supplier of the product.
  NOW, THEREFORE, in
        consideration of the mutual promises and covenants set forth herein, the
        parties
        agree as follows.
  1.  Supply. During
        the term of this Agreement, IMCOR shall purchase all of its requirements
        of
        Material for commercial manufacturing from Vendor and Vendor shall sell to
        IMCOR
        such quantities of the Material as ordered from time to time by IMCOR. Nothing
        herein shall limit Vendor's ability to supply Material to other
        customers.
  2.  Duration. This
        Agreement shall have effect upon execution and shall remain in effect for
        the
        initial term indicated on Exhibit "A" (the "Term") Thereafter, this Agreement
        shall be renewed automatically for successive two-year periods unless terminated
        by either party by written notice not later than eighteen months prior to
        expiration of the initial term or any renewal period.
  3.  Specification
        and Quality Control Standards; GMP Compliance.
  3.1  The
        quantities of the Material to be supplied hereunder shall be manufactured
        by
        Vendor in accordance with all applicable laws, rules and regulations, and
        in conformity
        with the specification and quality control standards set forth in Exhibit
        "B"
        attached hereto
        (collectively, the "Specifications"). If IMCOR wishes to change the
        Specifications, Vendor shall use its reasonable endeavors to carry out such
        change subject to agreement on a reasonable change (increase or decrease)
        in
        price, if appropriate, to reflect any costs or savings consequent thereon.
        Vendor shall consult with and must obtain written consent from IMCOR reasonably
        in advance of making any changes in the Specifications, or other aspect of
        the
        production, storage, and transport of Material which would or
        might:
  [****] Represents material which has been redacted pursuant to a request for
              confidential treatment pursuant to Rule 24B-2 under the Securities
              Exchange Act
              of 1934, as amended. The confidential materials have been filed separately
              with
              the SEC.
  (a)
              Cause
                  a potential change in the Material purity
                  profile;
  (b)
              Require
                  IMCOR to revalidate its own process or
                  methods;
  (c)
              Require
                  IMCOR to re-audit Vendor,
  (d)
              Require
                  IMCOR or Vendor to submit or resubmit any documentation to the
                  FDA.
  Subject
        to the foregoing, Vendor may otherwise alter the Specifications upon sixty
        days
        prior written notice to IMCOR.
  3.2  Vendor
        shall make available to IMCOR such data and information in relation to Material
        as is reasonably necessary to ascertain compliance with this Agreement and
        to
        qualify the use of Material in the Product with appropriate regulatory
        authorities. However, nothing
        here shall be construed as placing Vendor under an obligation to disclose
        to
        IMCOR any data
        relating to the actual production or purification of the Material except
        as
        Vendor deems appropriate for IMCOR to satisfy itself regarding the security
        or
        quality of supply of the Material or unless IMCOR is required to supply any
        such
        data to any appropriate regulatory authorities,
        in which case Vendor shall provide such information to IMCOR or arrange for
        direct disclosure to such regulatory authorities at IMCOR's expense. IMCOR may visit
        and inspect Vendor's facilities used in the Manufacture and testing of the
        Material once per year with reasonable prior notice.
  3.3  Vendor
        shall carry out the production and purification of the Material to be supplied
        hereunder in accordance with the U.S. Food and Drug Administration ("FDA")
        and
        Good Manufacturing Practice ("GMP") regulations and shall allow inspection
        of
        Vendor facilities by U.S. or foreign regulatory authority representatives
        to
        enable the said representatives to verify Vendor's compliance with GMP and
        all
        other relevant regulations. Vendor may altar the production and purification
        processes for the Material upon prior written notice to IMCOR but only if
        Vendor
        follows all appropriate regulatory procedures and obtains any relevant
        regulatory approvals and there is no change to the specification and quality
        control standards for the Material.
  4.  Estimates
        and Orders. As soon
        as practical after the effective date of this Agreement, and within the last **[****]** days of
        each calendar quarter thereafter, IMCOR shall deliver  to
        vendor
        a **[****]** **** month
        rolling Forecast (the "Forecast") of the quantity of material to be  purchased
        by IMCOR. The **[****]** of such
        Forecast will be considered a  firm
        commitment for production quantities and the remainder of the Forecast shall
        be
        advisory  only.
        Accordingly, the **[****]** quantity
        in each subsequent Forecast shall be identical to the  **[****]**  quantity
        in the previous "Forecast" unless the parties otherwise agree in
        writing. Within **[****]** days of
        delivery of each Forecast, IMCOR shall submit to Vendor a written delivery
        "Order" for the Material which shall represent the **[****]** firm
        commitment as illustrated by the Forecast.
  [****] Represents material which has been redacted pursuant to a request for
              confidential treatment pursuant to Rule 24B-2 under the Securities
              Exchange Act
              of 1934, as amended. The confidential materials have been filed separately
              with
              the SEC.
 5.  Delivery. The
        Material shall be supplied D.D.U. San Diego, California with any and all
        freight
        and packaging expenses being prepaid by Vendor and added to Vendor's invoice
        to
        IMCOR for payment by IMCOR. Title to and risk of loss of the Material shall
        pass
        to IMCOR at the time of delivery to a carrier designated by IMCOR or, if
        not
        delivered but stored by Vendor at IMCOR's request, at the time such Material
        is
        actually segregated and stored in facilities reasonably designed and maintained
        for storage of the materials. All shipments shall meet the specifications
        set
        forth in Exhibit "B" and be accompanied by a Certificate of Analysis. Material
        Orders shall be delivered to IMCOR in accordance with a delivery schedule
        provided by IMCOR in the Order, provided that no delivery be required to
        be made
        within one hundred and twenty (120) days of such Order.
  6.  Prices
        and Payment.
  6.1  IMCOR
        shall pay the prices specified in Exhibit "C" for the Material delivered
        by
        Vendor.
  6.2  The
        price
        does not include sales, use, excise or any other similar taxes imposed by
        Federal, state or local governments, and accordingly such taxes shall be
        paid by
        IMCOR.
  6.3  Invoices
        for Material shall be sent to IMCOR on or after the date of shipment of
        Material. Payment shall be made by IMCOR as follows: (1)  **[****]** of the
        payment for the Material in the Order (the "Order Payment") shall be paid
        upon
        submission of the Order pursuant to Section 4 hereof, (2)  **[****]** of the
        Order Payment shall be due upon delivery of the Material and (3)  **[****]** of the
        Order Payment shall be due within **[****]** days
        from the date of invoice, net of any and all invoice fees or other fees or
        charges, other than those specified in this Agreement.
  6.4  IMCOR
        shall pay Vendor a fee of **[****]** United
        States dollars **[****]**  per
        calendar quarter (the "Regulatory Fee") for costs incurred by Vendor that
        are associated with the filing and maintenance of the Drug Master File (DMF)
        and all
        supporting documentation. The first quarterly Regulatory Fee shall be due
        upon
        execution and delivery of this
        Agreement and the remaining quarterly Regulatory Fees shall be due on the
        first
        day of each  calendar
        quarter thereafter; provided
        however, that
        if
        IMCOR's total Orders in any calendar year exceed **[****]** United
        States dollars **[****]** ,
        IMCOR's
        obligation to pay the Regulatory Fee as set forth in this Section 6.4 shall
        terminate.
  7.  Confidentiality. Each
        party hereto (a "Recipient") recognizes that the other party hereto and its
        subsidiaries and affiliated corporations (a "Discloser") own or have licensed
        certain confidential information, including but not limited to secret or
        confidential data, proprietary information, trade secrets, technology, formulae,
        processes, procedures, scientific studies, regulatory submissions, business
        plans, information and the like, whether all of the same be in writing or
        not,
        and that Discloser has disclosed or may disclose to Recipient portions of such
        confidential information (all  of
        which
        is referred to as  "Confidential
        Information"). Use of  the
        Confidential Information shall
        be
        solely for the purposes of complying with
        this
        Agreement. Recipient agrees to maintain the confidential status of such
        Confidential Information and not to disclose the same to persons not authorized
        herein or otherwise authorized in writing by Discloser to receive such
        Confidential Information. Confidential Information shall not include information
        that was (4) in the
        public domain prior to the time of its disclosure under this Agreement; (5) entered
        the public domain after the time of its disclosure under this Agreement through
        means other than an unauthorized disclosure resulting from an act or omission
        by
        the receiving party; (6) was
        independently developed or discovered by the receiving party prior to the
        time
        of its disclosure under this Agreement; (7) is or
        was disclosed to the receiving party at any time, whether prior to or after
        the
        time of its disclosure under this Agreement, by a third party having no
        fiduciary relationship with the disclosing party and having no obligation
        of confidentiality
        with respect  to
        such  Confidential
        Information; or (8) is
        required to  be
        disclosed to comply
        with applicable laws or regulations, or with a court or administrative order,
        provided that the disclosing party receives prior written notice of such
        disclosure and that the receiving party takes all reasonable and lawful actions
        to obtain confidential treatment for such disclosure and, if possible, to
        minimize the extent of such disclosure
  
  8.  Termination
        / Breach. Notwithstanding any other provisions of this Agreement, either party, at
        its
        option, may terminate this Agreement;
  8.1  Should
        the other commit an act of bankruptcy, be declared bankrupt, voluntarily
        file or
        have voluntarily filed against it, a petition for bankruptcy or reorganization
        unless such petition is dismissed within 60 days of filing, enter into an
        arrangement for benefit or creditors, enter into a procedure of winding up
        or
        dissolution or should a Trustee or Receiver be appointed for its business,
        assets or operations; or
  8.2  Unless
        excused pursuant to Section 14 of this Agreement, upon 120 days written
        notice, should the other fail to comply with or to perform any of its
        obligations under this Agreement
        unless such failure or non-performance is corrected within the 120 day period
        following notification, or such extended period as shall be agreed between
        parties.
  8.3  If
        the
        FDA and all applicable foreign agencies fail to approve the Product or
        subsequently rescind the approval of the Product, by giving written notice
        thereof to the other party.
  8.4  Notwithstanding
        the foregoing, if Vendor fails to provide the material in accordance with
        this
        Agreement and the Order more that two times, IMCOR may by providing sixty
        (60)
        days written notice, change this Agreement into a nonexclusive purchase
        agreement. If Vendor is able to provide Material within the 60-day notice
        period
        set forth herein, this Agreement shall retain its exclusivity
        provision.
  9.  Limited
        Warranty. Vendor
        warrants that the Material shall be manufactured in accordance with all
        applicable laws, rules and regulations, according to cGMPs, and in conformity
        with Specifications. This warranty is in lieu of, and VENDOR SPECIFICALLY
        DISCLAIMS AND EXCLUDES, ALL OTHER WARRANTIES, EXPRESS, IMPLIED OR STATORY,
        INCLUDING THE WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR
        PURPOSE.
  
  10.  Limitation
        of Liability. Vendor
        will not under any circumstances be liable to IMCOR for incidental, special
        or
        consequential damages (including, but not limited to, loss of profits, revenue
        or business) resulting from or in any way related to a breach of any
        representation or warranty hereunder. This limitation does not apply to claims
        for personal injury by a third party.
  11.  Inspection. IMCOR
        shall stole Material under appropriate conditions and not later
        than 45 days after receipt of each consignment of the Material sold hereunder,
        IMCOR shall examine
        such consignments of the Material for compliance with the Specifications
        and
        shall notify Vendor of any non-compliance without delay within such 45 day
        period. In the event of any dispute as to the compliance of the Material
        with
        the Specifications, representative samples of the Material will be provided
        to
        an independent testing service (the "Testing Service) that shall
        be
        identified by mutual agreement within ninety (90) days of the date hereof,
        and
        the results provided
        by the Testing Service shall be finally determinative. The incorrect party
        shall
        be responsible for all costs incurred by the Testing Service. In no event
        shall
        acceptance relieve Vendor from any obligations under warranties, unless
        non-conformity should reasonably have been detected by IMCOR using reasonable
        diligence. Vendor shall replace any delivery of the Material that the Testing
        Service deems to be non-conforming as soon as possible, but in any event,
        within
        120 days of the date of receipt of notice thereof.
  12.  Indemnity .
  12.1  IMCOR
        shall indemnify, defend and hold harmless Vendor and its affiliates and each
        of
        their respective directors, officers, employees and agents against all claims,
        losses, damages and expenses, including attorneys' fees (collectively "Losses")
        relating to (9) any
        death or personal injury arising from use of the Product containing Material
        purchased hereunder, except those arising as a result of Vendor's negligence
        or
        a breach of Vendor's agreements, and warranties hereunder and (10) a breach
        of the terms of this Agreement by IMCOR. Vendor shall notify IMCOR of any
        such
        claim received by Vendor and IMCOR shall have the right to control the conduct
        of the defense or settlement of the claim. IMCOR shall at its own expense
        keep
        in force during the term of this Agreement as well as for a period of ten
        years
        thereafter adequately funded self-insurance or policies of insurance. Such
        insurance should provide coverage to the extent required by local laws and
        pharmaceutical industry practice. IMCOR shall upon the request of Vendor
        provide
        Vendor with a certificate of insurance or other documentation as proof of
        the
        insurance requirement herein.
  12.2  Vendor
        hereby agrees to
        indemnify, defend and hold harmless IMCOR and its affiliates, and each of
        their
        respective directors, officers and employees and agents, from and against
        any
        and all Losses incurred by IMCOR, based on or arising out of Vendor's breach
        of
        the limited warranty as set forth in Section 10 herein or Vendor's negligence.
        Vendor agrees to
        maintain in effect for the term of this Agreement and ten years thereafter
        adequately funded self-insurance or policies of insurance providing coverage
        to
        the extent required by local law and pharmaceutical industry
        practice.
  13.  Generic
        Drug Enforcement Act of 1992. Vendor
        represents that it and its employees have never been (11) debarred
        or (12) convicted of a crime for which a person can be debarred, under Section 306(a)
        or
        306(b) of the Generic Drug Enforcement Action of 1992. Vendor represents
        that it
        has never been and, to the best of its knowledge after due inquiry, none
        of its
        employees, affiliates or agents has ever been (a) threatened to be debarred
        or
        (b) indicted for a crime or otherwise engaged in conduct for which a person
        can
        be debarred, under Section 306(a) or (b). Vendor agrees that it will promptly
        notify IMCOR in the event of any such debarment, conviction, threat or
        indictment.
  
 14.  Force
        Majeure. If the
        performance by any party of any obligation under this Agreement
        other than the payment of money, is prevented or impaired by Force Majeure
        for
        any cause
        beyond the reasonable control of the defaulting party, such party shall be
        excused from performing so long as such situation continues to prevent or
        impair
        performance; provided the party
        claiming such excuse shall have promptly notified the other party of the
        existence, nature,  duration
        and other details of such cause and shall at all times use its reasonable
        effort
        to resume a  complete
        performance. If any party anticipates that a Force Majeure may occur that
        party
        shall notify
        the other immediately and explain the nature, details and expected duration
        thereof. The affected party will advise the other from time to time as to
        the
        progress in remedying the situation and as to the time when the affected
        party
        expects to resume its obligations and shall notify the others as to the
        expiration of any Force Majeure as soon as the affected party knows the
        date
        thereof. "Force Majeure" shall mean an event beyond the reasonable control
        of a
        party  including,
        but not limited to, fire, flood, sabotage, shipwreck, embargo, explosion,
        accident, riot, act of
        governmental authority (including, without limitation, acts relating to raw
        material or product allocation), acts of God and acts of war.
  15.  Records. All
        records relating to the manufacture of Material shall be retained for a period
        of not less than five years from the date of manufacture of Material or six
        months from the expiration of the final released Material, whichever is later.
        Prior to the destruction of any record, written notice shall be provided
        to
        IMCOR and IMCOR shall have the right to request and retain said
        records.
  16.  Notices. Any
        notice required or permitted to be given or made under this Agreement shall be
        in
        writing and sent by telefax or registered letter or by recognized overnight
        courier (i.e. Federal Express) to the other party at its address indicated
        on
        the first page of this Agreement, or to such other address as the addressee
        shall have furnished in writing. Notice shall be deemed received three days
        after deposit in the mail or, if sent by courier or facsimile, upon
        receipt.
  17.  Entire
        Agreement. The
        terms and provisions contained in this Agreement, constitute the entire
        Agreement between the parties with respect to the transactions contemplated
        hereby and shall supersede all previous communications. Representations,
        agreements or understandings, either oral or written, between the parties
        hereto
        with respect to the subject matter hereof, and no agreement or understanding
        varying or extending this Agreement will be binding upon either party hereto,
        unless in writing and signed by both parties.
  18.  Non-Waiver. Failure
        to terminate this Agreement following breach or failure to comply with this
        Agreement, shall not constitute a waiver of a party's defenses, rights or
        causes
        of action arising from such or any further breach or non-compliance. Any
        waiver
        must be expressly in writing. The waiver by any of the parties to this Agreement
        of any breach of any provision hereof by the other party or parties shall
        not be
        construed to be a waiver of a succeeding breach of such provisions or a waiver
        of the provision itself.
  
 19.  Severability
        and Survival. If and
        to the extent that any court, arbitrator or tribunal of
        competent jurisdiction holds any of the terms, provisions or conditions or
        parts
        thereof of this  Agreement
        or the application hereof to any circumstances, to be invalid or to be
        unenforceable in  a
        final
        non-appealable order, the remainder of this Agreement and  the
        application of such terms,  provisions
        or conditions or parts thereof to circumstances other than those as to which
        it
        is held invalid
        or unenforceable shall not be affected thereby, and each of the other terms,
        provisions and conditions of this Agreement shall be valid and enforceable
        to
        the fullest extent of the law. Sections 7, 10 and 12 shall survive and
        termination of this Agreement.
  20.  Assignment. Neither
        party shall at any time, without the prior written consent of the other party
        assign or otherwise transfer its rights or obligations under this Agreement
        in
        whole or in part to any other party whatsoever, provided that either party
        may
        assign or transfer its rights and obligations hereunder to a third party
        as part
        of a divestment or licensing of all or substantially all of the business
        to
        which this Agreement pertains and has the resources to comply with the terms
        of
        this agreement.
  21.  Controlling
        Provisions. In
        ordering and delivering supplies of the Material the parties may employ their
        standard forms; however, nothing contained on such forms shall be construed
        to modify, amend, add to or delete the terms of this Agreement and in the
        event
        of any conflict
        between them, the terms of this Agreement shall prevail.
  22.  Arbitration
        and Governing Law.
  22.1  In
        the
        event that any dispute arises out of this Agreement, the parties shall endeavor
        to settle such dispute amicably between themselves. In the event that the
        parties fail to achieve
        an amicable settlement of any such dispute, that dispute shall be submitted
        to
        arbitration  under
        the
        commercial arbitration rules of the American Arbitration Association and
        the
        award or decision
        made in such arbitration shall be final and binding upon the
        parties.
  22.2  This
        Agreement shall be governed by and construed and interpreted in accordance
        with
        the laws of the State of New York, with disregard to its conflicts of law
        rules.
  23.  Relationship
        of Parties. The
        relationship of parties under this Agreement is that of independent contractors.
        No party shall be deemed to be the partner or agent of the other, and no
        party
        is authorized to take any action binding upon the other.
  IN
        WITNESS WHEREOF, Vendor and IMCOR have caused this Agreement to be executed
        by
        their duly authorized officers as of the day and year first written
        above.
  IMCOR,
                  A DIVISION OF PHOTOGEN
                TECHNOLOGIES,
                  INC.
                JACK
                  DEFRANCO
                
                By:
                  /s/ Jack DeFranco
                Title:
                  Senior Vice President
              GENZYME
                  CORPORATION
                DANIEL
                  O’NEIL HAYDEN
                
                
                By:
                  /s/ Daniel O’Neil Hayden
                Title:
                  Senior Vice President & General
                  Manager
  [****] Represents material which has been redacted pursuant to a request for
              confidential treatment pursuant to Rule 24B-2 under the Securities
              Exchange Act
              of 1934, as amended. The confidential materials have been filed separately
              with
              the SEC.
  **Exhibit
        "A"**
 t o
        Supply
        Agreement
 between
        IMCOR, a Division of Photogen Technologies, Inc.
 and
 Genzyme
        Corporation
 
 1.
              Vendor
                  Material:
              1,2-Dimyristoyl-*sn*-glycero-3-phosphocholine,
                  Genzyme product code # LP-04-058, DMPC2.
              IMCOR
                  Product:
              IMAGENT
                  ® perflexane lipid microspheres3.
              Contract
                  Term:
              **[****]**years4.
              Pricing:
              A.
                  See Exhibit "C"
                
                B.
                  If government regulations or similar mandatory requirements causethe
                  cost to Vendor or raw materials to vary substantially, the
                  partiesshall meet to agree to a corresponding variation in the price of
                  the
                  Material.5.
              Primary
                  Contact:
              A.
                  IMCOR
                
                A
                  Division of Photogen Technologies, Inc.
                Address:
                  6175LuskBoulevard, San Diego, CA 92121
                Phone:
                  (858) 410-5601
                Fax:
                  (858) 410-5602
                
                B.
                  Vendor Genzyme Corporation
                Name:
                  William DeVroom
                Address:
                  One Kendall Square, Cambridge, MA 02139
                Phone:
                  (800) 868-8208
                Fax:
                  (617) 252-7772
  
   Exhibit
        "B"
 to
        Supply
        Agreement
 between
        IMCOR, a Division of Photogen Technologies, Inc.
 and
 Genzyme
        Corporation
 
 **SPECIFICATIONS
        AND QUALITY CONTROL STANDARDS**
  **See
        attachment "Component Purchase Specifications"**
   [****] Represents material which has been redacted pursuant to a request for
              confidential treatment pursuant to Rule 24B-2 under the Securities
              Exchange Act
              of 1934, as amended. The confidential materials have been filed separately
              with
              the SEC.
  **Exhibit
        "C"**
 to
        Supply
        Agreement
 between
        IMCOR, a Division of Photogen Technologies, Inc.
 and
 Genzyme
        Corporation
 
 **(SUBJECT
        TO MODIFICATION]**
  **PRICING**
  Increments
        purchased shall be aggregated with all purchases in the same year, with the
        total amount purchased reset to 0 on each January 1 during the term, and
        priced
        according to the schedule
        below. For example, if **[****]** kg was
        purchased in a calendar year, the first **[****]** kg would
        be priced
        at **[****]** and the
        additional **[****]** kg would
        be priced at **[****]** per
        kg.
  Product
              Amount
                  Purchased (kg)
              Price
                  per kg ($)1,2-Dimyristoyl-*sn*-
                glycero-3-phosphocholine,
                Genzyme
                  product code #
                LP-04-058,
                  DMPC
              **[****]**
              **[****]**1,2-Dimyristoyl-*sn*-
                glycero-3-phosphocholine,
                Genzyme
                  product code #
                12-04-058,
                  DMPC
              greater
                  than**[****]**kg
                  and less
                than
                  or equal to**[****]**kg
              **[****]**1,2-Dimyristoyl-*sn*-
                glycero-3-phosphocholine,
                Genzyme
                  product code #
                LP-04-058,
                  DMPC
              greater
                  than**[****]**kg
                  and less
                than
                  or equal to**[****]******kg
              **[****]**1,2-Dimyristoyl-*sn*-
                glycero-3-phosphocholine,
                Genzyme
                  product code #
                LP-04-058,
                  DMPC
              Greater
                  than**[****]**kg
              **[****]**